B16F10 Mouse Model Overview
The B16F10 tumor model is a widely used syngeneic melanoma model derived from murine melanoma cells and implanted in immunocompetent C57BL/6 mice. Characterized by aggressive tumor growth and poor responsiveness to immune checkpoint inhibition, this model serves as a stringent platform for evaluating novel immuno-oncology therapies. B16F10 is particularly valuable for investigating immune-resistant tumor biology, enabling robust assessment of therapeutic strategies designed to overcome resistance in the context of a fully functional immune system.
Why Choose the B16F10 Syngeneic Mouse Model?
- Immunocompetent system – Enables evaluation of therapies in the presence of a fully functional immune system
- Native tumor–immune interactions – Supports assessment of checkpoint inhibitors and immune-modulating agents in vivo
- Checkpoint inhibitor relevance – Facilitates evaluation of responses to anti-PD-1 and anti-CTLA-4 therapies
- Immune resistance insights – Ideal for studying mechanisms of tumor immune evasion and refractory biology
B16F10 Melanoma Tumor Model Characteristics
| Attribute | Description |
|---|---|
| Tumor Type | Melanoma |
| Cell Line | B16F10 |
| Mouse Strain | C57BL/6 |
| Immune Status | Fully immunocompetent |
| ICI Sensitivity | Non-responsive to checkpoint inhibitors |
| Notable Traits | Low immunogenicity; aggressive tumor progression |
Cancer Model Database
Support your in vitro, in vivo, and ex vivo studies with a user-friendly search, new model data (including HLA typing, growth curves, and tumor images), and multi-parameter search options for all tumor model types.
Visit Our Database
Immunotherapy Response Profile of B16F10 Tumor Model
The B16F10 model exhibits a consistently refractory response to immune checkpoint inhibition, making it a rigorous system for evaluating next-generation therapies.
- Anti-PD-1 – No meaningful antitumor response observed
- Anti-CTLA-4 – No significant monotherapy activity
- Combination (Anti-PD-1 + Anti-CTLA-4) – No meaningful improvement over monotherapy
This resistance profile positions B16F10 as a high-stringency benchmark model for testing novel immunotherapies, including combination strategies and immune-modulating approaches.
B16F10: Anti-CTLA-4 (9H10) / Anti-PD-1 (RMP1-14) Therapy
Figure 1: Therapeutic resistance in the B16F10 model.
Study Capabilities
In Vivo
- Subcutaneous and intravenous implantation
- Tumor growth and progression monitoring
- Bioluminescent imaging (e.g., B16F10-Luc) for longitudinal tracking
- Evaluation of metastatic disease
Dosing Routes
- Intravenous (tail vein), intraperitoneal, oral, subcutaneous, and intratumoral administration
Pharmacodynamic and Immune Analysis
- Tumor-infiltrating leukocyte (TIL) profiling via flow cytometry
- Cytokine and protein analysis (ELISA, Luminex)
- Gene expression analysis (qPCR, QuantiGene)
Patient‑Derived Xenograft (PDX) Models for Translational Oncology
Leverage clinically relevant PDX models that preserve patient tumor heterogeneity to improve confidence in efficacy, resistance, and biomarker evaluation across oncology drug development.
View Available Models
Ideal Applications of B16F10 Melanoma Model
- Evaluation of novel immunotherapies in refractory tumor settings
- Development of combination strategies to overcome checkpoint resistance
- Investigation of tumor immune evasion mechanisms
- Assessment of cell-based therapies and cancer vaccines
Related Capabilities
- Flow Cytometry and Immune Profiling – Comprehensive immune cell characterization
- Cytokine and Protein Analysis – ELISA and multiplex (Luminex) assays
- Gene Expression Analysis – qPCR and QuantiGene platforms
- In Vivo Imaging – Longitudinal tumor monitoring with luciferase models
- Cell-Based Assays – Proliferation, cytotoxicity, and IC50 evaluation
- Adoptive Cell Therapy Models – Antigen-specific T cell approaches
Need help designing a study or selecting the right syngeneic model for your program?